Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease

Personalised medicine, in which clinical management is individualised to the genotypic and phenotypic data of patients, offers a promising means by which to enhance outcomes in the management of mycobacterial pulmonary infections. In this review, we provide an overview of how personalised medicine a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kartik Kumar, Onn Min Kon
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	personalised medicine tuberculosis non-tuberculous mycobacteria risk factors nucleic acid amplification assays next generation sequencing Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/d6c82a88552844829c70de753318a9d5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d6c82a88552844829c70de753318a9d5
record_format	dspace
spelling	oai:doaj.org-article:d6c82a88552844829c70de753318a9d52021-11-25T18:24:20ZPersonalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease10.3390/microorganisms91122202076-2607https://doaj.org/article/d6c82a88552844829c70de753318a9d52021-10-01T00:00:00Zhttps://www.mdpi.com/2076-2607/9/11/2220https://doaj.org/toc/2076-2607Personalised medicine, in which clinical management is individualised to the genotypic and phenotypic data of patients, offers a promising means by which to enhance outcomes in the management of mycobacterial pulmonary infections. In this review, we provide an overview of how personalised medicine approaches may be utilised to identify patients at risk of developing tuberculosis (TB) or non-tuberculous mycobacterial pulmonary disease (NTM-PD), diagnose these conditions and guide effective treatment strategies. Despite recent technological and therapeutic advances, TB and NTM-PD remain challenging conditions to diagnose and treat. Studies have identified a range of genetic and immune factors that predispose patients to pulmonary mycobacterial infections. Molecular tests such as nucleic acid amplification assays and next generation sequencing provide a rapid means by which to identify mycobacterial isolates and their antibiotic resistance profiles, thus guiding selection of appropriate antimicrobials. Host-directed therapies and therapeutic drug monitoring offer ways of tailoring management to the clinical needs of patients at an individualised level. Biomarkers may hold promise in differentiating between latent and active TB, as well as in predicting mycobacterial disease progression and response to treatment.Kartik KumarOnn Min KonMDPI AGarticlepersonalised medicinetuberculosisnon-tuberculous mycobacteriarisk factorsnucleic acid amplification assaysnext generation sequencingBiology (General)QH301-705.5ENMicroorganisms, Vol 9, Iss 2220, p 2220 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	personalised medicine tuberculosis non-tuberculous mycobacteria risk factors nucleic acid amplification assays next generation sequencing Biology (General) QH301-705.5
spellingShingle	personalised medicine tuberculosis non-tuberculous mycobacteria risk factors nucleic acid amplification assays next generation sequencing Biology (General) QH301-705.5 Kartik Kumar Onn Min Kon Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease
description	Personalised medicine, in which clinical management is individualised to the genotypic and phenotypic data of patients, offers a promising means by which to enhance outcomes in the management of mycobacterial pulmonary infections. In this review, we provide an overview of how personalised medicine approaches may be utilised to identify patients at risk of developing tuberculosis (TB) or non-tuberculous mycobacterial pulmonary disease (NTM-PD), diagnose these conditions and guide effective treatment strategies. Despite recent technological and therapeutic advances, TB and NTM-PD remain challenging conditions to diagnose and treat. Studies have identified a range of genetic and immune factors that predispose patients to pulmonary mycobacterial infections. Molecular tests such as nucleic acid amplification assays and next generation sequencing provide a rapid means by which to identify mycobacterial isolates and their antibiotic resistance profiles, thus guiding selection of appropriate antimicrobials. Host-directed therapies and therapeutic drug monitoring offer ways of tailoring management to the clinical needs of patients at an individualised level. Biomarkers may hold promise in differentiating between latent and active TB, as well as in predicting mycobacterial disease progression and response to treatment.
format	article
author	Kartik Kumar Onn Min Kon
author_facet	Kartik Kumar Onn Min Kon
author_sort	Kartik Kumar
title	Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease
title_short	Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease
title_full	Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease
title_fullStr	Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease
title_full_unstemmed	Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease
title_sort	personalised medicine for tuberculosis and non-tuberculous mycobacterial pulmonary disease
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/d6c82a88552844829c70de753318a9d5
work_keys_str_mv	AT kartikkumar personalisedmedicinefortuberculosisandnontuberculousmycobacterialpulmonarydisease AT onnminkon personalisedmedicinefortuberculosisandnontuberculousmycobacterialpulmonarydisease
_version_	1718411227056570368

Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease

Ejemplares similares